Nhung Thi Hong Trinh

Nhung Thi Hong Trinh

Auto-generated profile, based on publicly available information

Nhung Thi Hong Trinh

PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
NTNhung Th Trinh
Nhung Th Trinh
AJAnnika M Jödicke
Annika M Jödicke
MCMartí Català
Martí Català
NMNúria Mercadé-Besora
Núria Mercadé-Besora
SHSaeed Hayati
Saeed Hayati
HNHedvig Me Nordeng
Hedvig Me Nordeng

1 May 2023 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
NTNhung T. H. Trinh
Nhung T. H. Trinh
TMTrine Munk-Olsen
Trine Munk-Olsen
NWNaomi R. Wray
Naomi R. Wray
VBVeerle Bergink
Veerle Bergink
HNHedvig M. E. Nordeng
Hedvig M. E. Nordeng
XLXiaoqin Liu
Xiaoqin Liu
Affective disorders are among the most common morbidities of pregnancy.1-3 Antidepressants constitute the mainstay of treatment for moderate to severe affective disorders for adults, including women of childbearing age.4 For individuals who respond to pharmaceutical treatment, long-term maintenance treatment with antidepressants is often needed to prevent recurrence.5

10 August 2022 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
RBRuben Burvenich
Ruben Burvenich
HDHannelore Dillen
Hannelore Dillen
NTNhung T H Trinh
Nhung T H Trinh
JFJoseph Freer
Joseph Freer
LWLaure Wynants
Laure Wynants
Jan VerbakelJan Verbakel
Jan Verbakel
Objective To determine the rate and appropriateness of antibiotic prescribing for acutely ill children in ambulatory care in high-income countries. Design On 10 February 2021, we systematically searched articles published since 2000 in MEDLINE, Embase, CENTRAL, Web Of Science and grey literature databases. We included cross-sectional and longitudinal studies, time-series analyses, randomised controlled trials and non-randomised studies of interventions with acutely ill children up to and including 12 years of age in ambulatory care settings in high-income countries. Pooled antibiotic prescribing and appropriateness rates were calculated using random-effects models. Meta-regression was performed to describe the relationship between the antibiotic prescribing rate and study-level covariates. Results We included 86 studies comprising 11 114 863 children. We found a pooled antibiotic prescribing rate of 45.4% (95% CI 38.2% to 52.8%) for all acutely ill children, and 85.6% (95% CI 73.3% to 92.9%) for acute otitis media, 37.4% (95% CI 30.9% to 44.3%) for respiratory tract infections, and 40.4% (95% CI 29.9% to 51.9%) for other diagnoses. Considerable heterogeneity can only partly be explained by differences in diagnoses. The overall pooled appropriateness rate is 68.5% (95% CI 55.8% to 78.9%, I²=99.8%; 19 studies, 119 995 participants). 38.3% of all prescribed antibiotics were aminopenicillins. Conclusions Antibiotic prescribing rates for acutely ill children in ambulatory care in high-income countries remain high. Large differences in prescription rates between studies can only partly be explained by differences in diagnoses. Better registration and further research are needed to investigate patient-level data on diagnosis and appropriateness.

11 October 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
NTNhung T.H. Trinh
Nhung T.H. Trinh
TBTim A. Bruckner
Tim A. Bruckner
MLMagali Lemaitre
Magali Lemaitre
FCFrançoise Chauvin
Françoise Chauvin
CLCorinne Levy
Corinne Levy
JCJérémie F. Cohen
Jérémie F. Cohen

17 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKristin Kostka
Kristin Kostka
ERElena Roel
Elena Roel
NTNhung T. H. Trinh
Nhung T. H. Trinh
NMNúria Mercadé-Besora
Núria Mercadé-Besora
ADAntonella Delmestri
Antonella Delmestri
AJAnnika M. Jödicke
Annika M. Jödicke
Persistent symptoms following the acute phase of COVID-19 present a major burden to both the affected and the wider community. We conducted a cohort study including over 856,840 first COVID-19 cases, 72,422 re-infections and more than 3.1 million first negative-test controls from primary care electronic health records from Spain and the UK (Sept 2020 to Jan 2022 (UK)/March 2022 (Spain)). We characterised post-acute COVID-19 symptoms and identified key symptoms associated with persistent disease. We estimated incidence rates of persisting symptoms in the general population and among COVID-19 patients over time. Subsequently, we investigated which WHO-listed symptoms were particularly differential by comparing their frequency in COVID-19 cases vs. matched test-negative controls. Lastly, we compared persistent symptoms after first infections vs. reinfections.Our study shows that the proportion of COVID-19 cases affected by persistent post-acute COVID-19 symptoms declined over the study period. Risk for altered smell/taste was consistently higher in patients with COVID-19 vs test-negative controls. Persistent symptoms were more common after reinfection than following a first infection. More research is needed into the definition of long COVID, and the effect of interventions to minimise the risk and impact of persistent symptoms.

25 May 2020 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
NTNhung T H Trinh
Nhung T H Trinh
RCRobert Cohen
Robert Cohen
MLMagali Lemaitre
Magali Lemaitre
PCPierre Chahwakilian
Pierre Chahwakilian
GCGregory Coulthard
Gregory Coulthard
JCJérémie F. Cohen
Jérémie F. Cohen
Objectives: To assess recent community antibiotic prescribing for French children and identify areas of potential improvement. Methods: We analysed 221 768 paediatric (<15 years) visits in a national sample of 680 French GPs and 70 community paediatricians (IQVIA’s EPPM database), from March 2015 to February 2017, excluding well-child visits. We calculated antibiotic prescription rates per 100 visits, separately for GPs and paediatricians. For respiratory tract infections (RTIs), we described broad-spectrum antibiotic use and duration of treatment. We used Poisson regression to identify factors associated with antibiotic prescribing. Results: GPs prescribed more antibiotics than paediatricians [prescription rate 26.1 (95% CI 25.9–26.3) versus 21.6 (95% CI 21.0–22.2) per 100 visits, respectively; P < 0.0001]. RTIs accounted for more than 80% of antibiotic prescriptions, with presumed viral RTIs being responsible for 40.8% and 23.6% of all antibiotic prescriptions by GPs and paediatricians, respectively. For RTIs, antibiotic prescription rates per 100 visits were: otitis, 68.1 and 79.8; pharyngitis, 67.3 and 53.3; sinusitis, 67.9 and 77.3; pneumonia, 80.0 and 99.2; bronchitis, 65.2 and 47.3; common cold, 21.7 and 11.6; bronchiolitis 31.6 and 20.1; and other presumed viral RTIs, 24.1 and 11.0, for GPs and paediatricians, respectively. For RTIs, GPs prescribed more broad-spectrum antibiotics [49.8% (95% CI 49.3–50.3) versus 35.6% (95% CI 34.1–37.1), P < 0.0001] and antibiotic courses of similar duration (P = 0.21). After adjustment for diagnosis, antibiotic prescription rates were not associated with season and patient age, but were significantly higher among GPs aged ≥50 years. Conclusions: Future antibiotic stewardship campaigns should target presumed viral RTIs, broad-spectrum antibiotic use and GPs aged ≥50 years.